ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - olaparib - טבליות מצופות פילם - olaparib 100 mg - olaparib

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - olaparib - טבליות מצופות פילם - olaparib 150 mg - olaparib

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - olaparib - טבליות מצופות פילם - olaparib 150 mg - olaparib

ישראל - עברית - Ministry of Health

astra zeneca (israel) ltd - olaparib - קפסולה קשיחה - olaparib 50 mg - olaparib

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - trastuzumab - תמיסה לאינפוזיה - trastuzumab 440 mg/ml - trastuzumab - trastuzumab - herceptin is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2: 1. as a single agent for the treatment of those patients who have received one or more chemotherapy regiments for their metastatic disease. 2. in combination with paclitaxel or docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease. 3. herceptin in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive metastatic breast cancer. early breast cancer (ebc) :herceptin is indicated to treat patients with her2-positive early breast cancer following surgery and chemotherapy (neoadjuvant or adjuvant) either alone or in combination with chemotherapy excluding anthracyclines. herceptin should only be used in patients whose tumors have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay.her2 metastatic gastric cancer (mgc)herceptin in

ישראל - עברית - Ministry of Health

novartis israel ltd - lapatinib as ditosylate monohydrate - טבליות מצופות פילם - lapatinib as ditosylate monohydrate 250 mg - protein kinase inhibitors - tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2);• in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting (see section 5.1).• tykerb is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.

ישראל - עברית - Ministry of Health

dexcel ltd, israel - trastuzumab - trastuzumab 420 mg/vial - trastuzumab

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - trastuzumab - תמיסה להזרקה - trastuzumab 600 mg / 5 ml - trastuzumab

ישראל - עברית - Ministry of Health

eisai israel ltd., israel - lenvatinib as mesilate - קפסולה קשיחה - lenvatinib as mesilate 10 mg - lenvatinib

ישראל - עברית - Ministry of Health

eisai israel ltd., israel - lenvatinib as mesilate - קפסולה קשיחה - lenvatinib as mesilate 4 mg - lenvatinib